These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
187 related articles for article (PubMed ID: 21885956)
1. Deep vein thrombosis induced by thalidomide to control epistaxis secondary to hereditary haemorrhagic telangiectasia. Penaloza A; Vekemans MC; Lambert C; Hermans C Blood Coagul Fibrinolysis; 2011 Oct; 22(7):616-8. PubMed ID: 21885956 [TBL] [Abstract][Full Text] [Related]
2. [Treatment of epistaxes in hereditary haemorrhagic telangiectasia (Rendu-Osler-Weber disease) with tranexamic acid]. Morales-Angulo C; Pérez del Molino A; Zarrabeitia R; Fernández A; Sanz-Rodríguez F; Botella LM Acta Otorrinolaringol Esp; 2007 Apr; 58(4):129-32. PubMed ID: 17428407 [TBL] [Abstract][Full Text] [Related]
3. Thalidomide for Epistaxis in Patients with Hereditary Hemorrhagic Telangiectasia: A Preliminary Study. Fang J; Chen X; Zhu B; Ye H; Zhang W; Guan J; Su K Otolaryngol Head Neck Surg; 2017 Aug; 157(2):217-221. PubMed ID: 28418273 [TBL] [Abstract][Full Text] [Related]
4. Thalidomide for the Management of Bleeding Episodes in Patients with Hereditary Hemorrhagic Telangiectasia: Effects on Epistaxis Severity Score and Quality of Life. Baysal M; Ümit EG; Kırkızlar HO; Özdöver AC; Demir AM Turk J Haematol; 2019 Feb; 36(1):43-47. PubMed ID: 29880465 [TBL] [Abstract][Full Text] [Related]
5. The use of thalidomide therapy for refractory epistaxis in hereditary haemorrhagic telangiectasia: systematic review. Harrison L; Kundra A; Jervis P J Laryngol Otol; 2018 Oct; 132(10):866-871. PubMed ID: 30191780 [TBL] [Abstract][Full Text] [Related]
7. The natural history of epistaxis in patients with hereditary hemorrhagic telangiectasia in the Norwegian population: a cross-sectional study. Dheyauldeen S; Abdelnoor M; Bachmann-Harildstad G Am J Rhinol Allergy; 2011; 25(4):214-8. PubMed ID: 21819756 [TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of thalidomide for the treatment of severe recurrent epistaxis in hereditary haemorrhagic telangiectasia: results of a non-randomised, single-centre, phase 2 study. Invernizzi R; Quaglia F; Klersy C; Pagella F; Ornati F; Chu F; Matti E; Spinozzi G; Plumitallo S; Grignani P; Olivieri C; Bastia R; Bellistri F; Danesino C; Benazzo M; Balduini CL Lancet Haematol; 2015 Nov; 2(11):e465-73. PubMed ID: 26686256 [TBL] [Abstract][Full Text] [Related]
9. Pulmonary arteriovenous malformations etiologies in HHT patients and potential utility of thalidomide. Lacout A; Marcy PY; El Hajjam M; Lacombe P Med Hypotheses; 2013 May; 80(5):587-8. PubMed ID: 23452644 [TBL] [Abstract][Full Text] [Related]
10. Intranasal tranexamic acid for the treatment of hereditary hemorrhagic telangiectasia: a case report and review of treatment options. Flanagan BA; Collins C; Parra S Cutis; 2012 Feb; 89(2):69-72. PubMed ID: 22474728 [TBL] [Abstract][Full Text] [Related]
11. Antiestrogen therapy for hereditary hemorrhagic telangiectasia: a double-blind placebo-controlled clinical trial. Yaniv E; Preis M; Hadar T; Shvero J; Haddad M Laryngoscope; 2009 Feb; 119(2):284-8. PubMed ID: 19160429 [TBL] [Abstract][Full Text] [Related]